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Abstract Neuroendocrine c lls can be demonstrated in 
normal, hyperplastic and neoplastic prostatic tissues. The 
products ecreted by these cells can be used as tissue and/or 
serum markers but may also have biological effects. Neu- 
roendocrine cells in prostate cancer most probably do not 
contain the androgen receptor and are therefore primarily 
androgen independent. Some of the neuropeptides secreted 
by the neuroendocrine c lls may act as growth factor by 
activation of membrane r ceptors in an autocrine-paracrine 
fashion or by ligand-independent activation of the andro- 
gen receptor in neighboring non-neuroendocrine cells. Ev- 
idence is accumulating from experiments with tumor mod- 
els that neuropeptides indeed can influence the growth of 
prostatic tumor cells. Future research on neuroendocrine 
differentiation may answer some questions concerning the 
biological behavior of clinical prostatic tumors. 
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Experimental models 
In most developed countries prostate cancer has become 
the most prevalent tumor in men and in these countries its 
mortality is only surpassed by that due to lung cancer [74, 
106]. Much research done in the field of prostate cancer is 
directed towards the identification of factors involved in 
tumor progression and the change from androgen depen- 
dency towards independency. Neuroendocrine differenti- 
ation is a possible factor which has received increasing at- 
tention during the past few years [74]. 
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Neuroendocrine (NE) cells are also known as APUD 
(amine precursor uptake and decarboxylation) cells or en- 
docrine-paracrine c lls [77]. The concept of NE/APUD 
cells was worked out by Pearse and coworkers from the 
diffuse endocrine pithelial organ concept of Feyrter [42, 
77]. The APUD system consists of a group of apparently 
unrelated endocrine cells located in endocrine and non-en- 
docrine tissues, which share a number of cytochemical, 
ultrastructural nd functional characteristics [77]. In more 
detail, the endocrine/NE system consists of: the classical 
endocrine organs (e.g., adrenals, parathyroid gland), clus- 
ters of endocrine cells (e.g., pancreatic islets of Lange- 
rhans), dispersed epithelial endocrine cells (e.g., gastroin- 
testinal NE cells), neurons and ganglia and the paragang- 
lion system [39]. 
The clinical aspects of NE differentiation i prostatic 
carcinoma have been reviewed in more detail in a number 
of papers by Di Sant'Agnese [30-32]. This review will 
therefore mphasize the experimental spects: the role of 
NE cells in androgen insensitivity, tumor growth and pro- 
gression. Nevertheless, some clinical data will be provided 
to better understand the concept and the questions that 
emerge from it. 
Neuroendocrine cells in the normal prostate 
In normal prostatic epithelium, NE cells are found among 
the well-known prostate specific antigen (PSA) producing 
exocrine cells and basal cells (Fig. 1) [2]. Such cells were 
described for the first time by Pretl in 1944 as the argen- 
taffin basal cells [84]. In this study the argentaffin cells 
were identified by silver staining procedures as well as au- 
to fluorescence t chniques [84]. Prostatic NE cells are lo- 
cated in the glandular and ductal epithelium and they form 
only a small part of the epithelial cell compartment. They 
clearly belong to the "dispersed epithelial endocrine cell" 
type [39]. NE cells are found throughout the whole pros- 
tate although they are more abundant in the periurethral 
and ductal regions [23]. In the guinea pig prostate the hum- 
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Fig. la, b Prostatic neuroendocrine cells, a Closed-type neuroen- 
docrine cell with cytoplasmic process (arrow). b Open-type n uro- 
endocrine cell. Chromogranin A staining with immunoperoxidase 
technique, nuclear counterstaining with hematoxylin, x900 
ber of NE cells increases with age [38], a phenomenon 
which has not been described for humans [23]. NE cells in 
the glandular cini but not in the periurethral and ductal 
epithelium of the human prostate w re found to disappear 
soon after birth and to reappear at puberty [23]. These find- 
ings suggest a direct or indirect effect of circulating andro- 
gens on the acinar NE cells but not on periurethral nd duc- 
tal NE cells. 
Morphologically, two types of prostatic NE cells can be 
recognized: a closed type separated by other cells from the 
lumen (Fig. la) and an open type reaching to the glandu- 
lar lumen (Fig. lb) [37]. The closed type often has den- 
dritic cytoplasmic processes interdigitating between 
neighboring cells [37]. Prostatic NE cells are ultrastructu- 
rally characterized by so-called ense core granules or neu- 
rosecretory granules [36]. Based on the variations in the 
ultrastructural morphology of the granules a greater het- 
erogeneity of NE cells has been suggested [36]. 
The heterogeneity of this cell type is also apparent from 
the variety of products (biogenic amines or peptide hor- 
mones) which they secrete. Chromogranin A and B (CgA 
and CgB), secretogranin II, neuron-specific enolase (NSE) 
and serotonin (5-HT) are found in most, if not all, prostatic 
NE ceils [3, 8, 37, 90]. A small number of these cells also 
contain calcitonin (CT) and related peptides uch as cal- 
citonin gene related peptide (CGRP) and katacalcin [27, 
29, 35, 40, 94]. In addition, somatostatin (SMS) [27, 34], 
bombesin/gastrin-related p ptide (GRP) [29], fl-chain 
midportion of thyroid-stimulating hormone [1, 4], glyco- 
protein hormone o~-chain [41 ] and parathyroid hormone re- 
lated protein have been found [50]. 
The chromogranins are acidic glycoproteins which are 
widely expressed in NE cells [112]. Various biologically 
active peptides can be released from the CgA and CgB mole- 
cules by enzymatic action [68, 112]. A third chromogranin 
(chromogranin C) is now known as secretogranin II [48, 
112]. Most of the immunohistochemical studies on NE dif- 
ferentiation have been performed with antibodies pecific 
for CgA or 5-HT. NSE (~enolase, a subtype of the glyco- 
lytic enzyme nolase) was thought to be an exclusive marker 
of endocrine and NE cells, but it has been shown that NSE 
is secreted by a large variety of other cell types [49]. 
The heterogeneous morphology of the neurosecretory 
granules and the diversity of secreted products suggest that 
these cells exert a number of distinct functions, which so 
far have been virtually unknown. In parallel with functions 
of NE cells in more extensively studied systems (i.e., lung, 
pancreas and adrenals), a role of these cells in growth and 
differentiation, and in maintenance of homeostasis has 
been suggested [47, 99, 111]. Some of the neuropeptides 
share growth factor activity (reviewed in [25, 92, 105]). 
Relatively high levels of CT, GRPPoombesin and SMS have 
been found in human semen [45, 88, 98]. Exposure to sal- 
mon-CT (sCT) decreased sperm motility in vitro [44]. Fur- 
thermore, sCT also increased the secretion of prostatic al- 
kaline phosphatase by rat ventral prostate xplants in a 
dose-dependent manner [61]. These studies indicate that 
prostatic NE cells might also have some exocrine func- 
tions. 
According to Feyrter's original concept of the diffuse 
endocrine organ, all NE cells throughout the body were 
thought o originate from the neural crest [59]. However, 
nowadays a local origin of the NE cells in most tissues is 
suggested and has been proven, for example, in colorectal 
epithelium [59]. A multidirectional differentiation has 
been postulated for normal tissues as well as for tumors 
arising in these tissues (reviewed by DeLellis [28])i In a 
recent immunohistochemical study, some prostatic NE 
cells expressed basal cell specific cytokeratins and a few 
NE cells in hyperplastic glands displayed immunoreactiv- 
ity for PSA [8, 17]. These observations suggest acommon 
differentiation pathway of prostatic secretory, NE and ba- 
sal cells and it is now generally accepted that prostatic NE 
cells indeed originate from the prostate. It may be hypoth- 
esized that the basal cell layer contains the prostatic stem 
cells and that these cells give rise to both the exocrine and 
NE phenotypes of the glandular epithelium. 
Neuroendocrine cells in the hyperplastic prostate 
The presence of NE cells in hyperplastic prostatic tissue 
h~ s been demonstrated using silver staining techniques [ 10, 
57]. In one study, up to 16 out of 20 hyperplastic nodules 
displayed NE differentiation [10]. However, in another 
study it was found that hyperplastic nodules in general con- 
tained less argentaffin NE cells than the adjacent normal 
epithelium [57]. This was confirmed in a recent study us- 
ing immunohistochemistry with a 5-HT antibody and chro- 
matographic quantification of the 5-HT content of tissue 
homogenates [20]. On the other hand, Abrahamsson etal. 
[3] found more NE cells in hyperplastic prostatic tissue 
than in normal glands as defined by immunoreactivity for 
5-HT, thyroid-stimulating hormone and CT. Aprikian et al. 
[8] found immunohistochemically defined NE cells in all 
investigated hyperplastic specimens, although their rela- 
tionship with the adjacent normal glands was not studied. 
Whether or not neuroendocrine c lls play a role in the path- 
ogenesis of benign prostatic hyperplasia s not clear at the 
moment. The study of Cockett et al. [20] gives some sup- 
port to this idea since they found more NE cells in small 
hyperplastic nodules than in normal prostate or large hy- 
perplastic nodules. This suggests that the growth of the 
more immature small hyperplastic nodules is stimulated by 
NE products. Alternatively, the presence of NE cells may 
simply reflect an enhanced proliferative activity of glan- 
dular epithelial cells in prostatic hyperplasia. 
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Neuroendocrine cells in the neoplastic prostate 
NE cells can be identified in prostate cancers (Fig. 2), al- 
though the percentage of tumors with NE cells varies in 
the literature from about 10% to almost 100%. This vari- 
ation partially reflects the development oftechniques used 
to identify NE cells. An extensive recently published study 
indicated that NE cells are present in about 60% of pros- 
tate cancers [8]. Two papers on the argentaffin cells in the 
hyperplastic and neoplastic prostate were published in the 
1970s [10, 57], but only recently have NE cells in prostate 
cancer gained increasing attention, 
According to Di Sant'Agnese [31], the term NE diffe- 
rentiation in prostate cancer includes the pathological cat- 
egories mall cell prostate cancer (SCPC), prostatic arci- 
noid, adenocarcinoma with scattered NE cells and mixed 
tumors of these three types. A relatively small proportion 
of prostatic adenocarcinomas with NE differentiation con- 
tain NE cells with large eosinophilic granules. This phe- 
nomenon was termed Paneth cell like change [6]. Very re- 
cently it has been suggested that these cells be renamed 
"NE cells with large eosinophilic granules" [6, 33]. Obvi- 
ously, the tumors with this type of NE cell also fit in the 
category of prostate cancer with NE differentiation. From 
a clinical point of view, prostate cancer with evidence of 
eutopic or ectopic production of neuroendocrine hormones 
and/or markers and prostatic malignancies a sociated with 
paraneoplastic syndromes linked to NE differentiation 
should also be included in the definition [31]. 
Undifferentiated small cell cancers, also referred to as 
NE carcinomas, occur in various organs, but most often in 
the lungs. SCPC is a relatively rare disease, accounting for 
+1-5% of all prostate cancers, and has been described in 
a few larger studies [76, 86, 91,104]. It is a highly malig- 
nant disease with a mean survival time of 7-17 months [76, 
104]. In about half of the patients the small cell compo- 
nent is preceded by a common adenocarcinoma, suggest- 
ing that at least in a number of patients the small cell car- 
cinoma arises in a common adenocarcinoma. In line with 
this suggestion, a number of mixed tumors have b en found 
[76, 104]. Not all SCPC showed NE differentiation, how- 
ever [86]. Prostatic carcinoid is a very rare entity. Only 
some case reports have been published as yet [7, 43, 67, 
101, 109, 110]. Carcinoids occur especially in the diges- 
tive system (appendix) and they are in general relatively 
Fig. 2 Prostatic adenocarcinoma with neuroendocrine cells. Chro- 
mogranin A staining with immunoperoxidase technique, nuclear 
counterstaining with hematoxylin, x 175 
benign [46]. It appears that prostatic arcinoid tumors be- 
have more aggressively [31, 101], although detailed stud- 
ies with follow-up data are lacking. Mixed carcinoid-aden- 
ocarcinoma tumors have been found and it has been sug- 
gested that carcinoid formation in a hormonally treated 
adenocarcinoma might be a selective ffect of the treat- 
ment [101]. 
The most common pattern of NE differentiation in pros- 
tate cancer is a prostatic adenocarcinoma with scattered 
NE cells. The number of NE cells within an adenocarcin- 
oma varies from patient o patient and their presence may 
have prognostic significance [5, 18, 21, 22, 26]. Some au- 
thors found a relationship between the tumor grade and the 
number of NE cells [4, 5], but others did not [8]. NE cells 
were identified in about 50% of lymph node and bone me- 
tastases of prostatic adenocarcinomas [9]. This proves that 
NE cells are an intrinsic component of the adenocarcin- 
oma and are not derived from preexistent benign glands. 
The presence of NE cells in metastatic lesions had no prog- 
nostic value [9]. Serum levels of CgA showed a 60% cor- 
relation with the immunohistochemical staining of this 
protein, and the presence of metastatic disease was better 
predicted by serum CgA levels than by tissue immunoreac- 
tivity [70]. The possible correlation between tumor grade 
and the number of NE cells in a tumor may well account 
for part or all of the reported prognostic value of NE dif- 
ferentiation, which would indicate that the number of NE 
cells just reflects the level of dedifferentiation f a tumor. 
This possibility can be investigated with long-term clini- 
cal follow-up studies using multiple regression analysis. 
Secretion products and hormone sensitivity 
NE cells in prostatic tumors are most often recognized by 
their immunoreactivity forNE markers (CgA, NSE) or eu- 
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Fig. 3 Androgen receptor (AR) and chromogranin A (CgA) double 
labeling in a benign prostatic gland. Nuclear AR staining with im- 
munofluorescence technique (FITC, originally green). CgA staining 
with alkaline phosphatase technique (originally red fluorescence sig- 
nal). Most epithelial cells display a strong AR positivity (arrow- 
heads). The triangular-shaped closed-type neuroendocrine cell (a - 
row) is AR negative, x250 (Reproduced from [60] with kind permis- 
sion) 
tiation, CgB replaced CgA expression by NE cells [90]. 
This implies that in immunohistochemical studies CgA as 
well as CgB immunoreactivity has to be assessed. 
Kadmon et al. demonstrated levated CgA serum lev- 
els in 12 out of 25 patients with metastatic, hormone-in- 
sensitive prostate cancer [55]. Moreover, in 4 of these 12 
patients PSA levels were in the normal range. Serum lev- 
els of NSE were found to be increased more often in pa- 
tients with hormone refractory tumors (10/46) than in pa- 
tients with hormone-sensitive tumors (2/89) [103]. Abra- 
~hamsson et al. studied NE differentiation i repeated bi- 
opsy specimens of patients treated with hormonal therapy 
or with radiotherapy [5]. They found mostly an increasing 
number of NE cells during follow-up paralleled by dedif- 
ferentiation and hormonal escape (i.e., progression) of the 
tumor. These results raise the question whether NE cells 
in prostate tumors are androgen sensitive or not. NE cells 
in benign and malignant prostatic tissues contained rarely, 
if at all, androgen receptor immunoreactivity (Fig. 3) [16, 
60]. In another study, using a different antibody for the an- 
drogen receptor, prostatic NE cells generally expressed the 
androgen receptor [71]. Very recently the authors of the 
latter study confirmed the findings of the former two stud- 
ies [33], leading to the conclusion that NE cells in the nor- 
mal or neoplastic prostate do not contain the androgen re- 
ceptor. It has been shown that the androgen receptor con- 
tent of a prostatic tumor does not predict androgen (in)sen- 
sitivity [87,107]. It is, however, unlikely that androgen re- 
ceptor negative tumor cells will respond to androgen with- 
drawal. Therefore, NE cells in prostate cancer most prob- 
ably form a primarily androgen-insensitive umor cell pop- 
ulation. 
Fig. 4 Influence of a neuroendocrine (NE) cell on neighboring non- 
NE cells (working hypothesis), t actions O f androgens mediated by
the nuclear androgen receptor (A), 2, 3, 4 action of neuropeptides r - 
leased from the neurosecretory vesicles (C) of the NE cell, 2 para- 
crine stimulation of eighboring non-NE cell by activation of neu- 
ropeptide receptor, 3 autocrine stimulation, 4 ligand-independent ac- 
tivation of androgen receptor in non-NE cell, 5 systemic action of 
neuropeptides s creted into the blood (paraneoplastic symptoms), 6 
stromal effects of neuropeptides 
topic bioactive peptides (5-HT, CT, SMS and others). In 
addition to the eutopic peptide products, a number of ec- 
topic peptides have been found, for example, adrenocor- 
ticotropic hormone (ACTH), leu-enkephalin a d ]3-endor- 
phin [4]. Expression of these factors, especially ACTH, 
might cause a paraneoplastic syndrome as occasionally 
found in prostate cancer patients (reviewed by Matzkin and 
Braf [65]). In high-grade tumors with marked NE differen- 
Growth modulation by neoplastic neuroendocrine cells 
A number of peptides produced by NE prostatic tumor cells 
(5-HT, GRP/bombesin, CT, SMS) exhibit growth factor ac- 
tivities mediated by a membrane receptor. This may rep- 
resent a way of paracrine or autocrine growth modulation 
[25, 92, 111]. Most of the prostatic adenocarcinoma cells 
surrounding NE cells contain the androgen receptor, even 
in androgen refractory carcinomas [16, 60]. It was found 
in COS cells transfected with steroid hormone receptors 
that dopamine activated several steroid hormone receptors 
(pr gesterone, strogen, vitamin D and thyroid hormone 
R-receptors) in a ligand-independent fashion [83]. In this 
way NE tumor cells might influence the growth of neigh- 
boring non-NE tumor cells by androgen-independent acti- 
vation of the androgen receptor in a paracrine manner. It 
is, however, not known yet if the androgen receptor can be 
activated similarly b neuropeptides and, therefore, this 
should be studied first. It should be stressed that neuropep- 
tides may enhance or inhibit growth, depending on the spe- 
cific nature of the neuropeptide and properties of the tar- 
get cell. Bonkhoff et al. found in an immunohistochemical 
study that proliferating cells in normal, hyperplastic and 
cancerous prostatic tissues were usually, but not necessar- 
ily, located in the proximity of clusters of NE cells [15]. 
This supports the concept of paracrine growth regulation 
by prostatic NE cells. 
The following hypothesis can be postulated: NE cells 
in a prostatic adenocarcinoma form a subset of primarily 
androgen-independent tumor cells which modulate the 
growth of neighboring non-NE tumor cells by the secre- 
tion of neuropeptides in a paracrine manner (Fig. 4). 
Granted this hypothesis, one would expect hat following 
androgen withdrawal the proportion of NE cells would in- 
crease. Abrahamsson etal. described in a group of 24 hor- 
mortally treated patients that the number of NE cells in- 
creased in time, although this was paralleled by dediffe- 
rentiation of the tumors (see above) [5]. Aprikian et al. 
were not able to confirm the observed increase in NE dif- 
ferentiation following short- or long-term hormonal ther- 
apy, however [8]. Larger follow-up studies on long-term 
androgen-depleted umors with assessments of absolute 
and relative numbers of NE cells should confirm the oc- 
currence of this phenomenon. Even if the NE cell popula- 
tion does not increase following androgen withdrawal, the 
secreted neuropeptides may still stimulate the surrounding 
non-NE cells by acting as "androgen substitutes." The se- 
creted neuropeptides may also have effects on stromal cells 
(stromal-epithelial interactions), a possibility which has 
not been studied as yet. 
Specific neuropeptides 
Serotonin 
Serotonin (5-HT) is well known as a neurotransmitter and 
vasoactive peptide and some recent reports indicate that 
5-HT also has growth factor activity [56, 93]. 5-HT stim- 
ulated DNA synthesis n hamster fibroblasts proved to be 
mediated by activation of the 5-HTlb receptor [93]. This 
receptor isonly expressed inrodents. Further experiments 
indicated that in humans 5-HT mediates the proliferation 
of smooth muscle cells mediated through activation of the 
5-HTld receptor [56]. 5-HT might influence tumor growth 
indirectly by changing the local blood flow in a tumor due 
to its vasoactive action. It is very likely that 5-HT plays a 
role in the prostate since it is expressed by most if not all 
prostatic NE cells [3, 8, 37]. Unfortunately, it is as yet not 
known if human prostatic tumor cells contain 5-HT recep- 
tors and, if so, which subtypes. If prostatic tumor cells con- 
tain 5-HT receptors, 5-HT may also exert its effect by li- 
gand-independent activation of the androgen receptor [83]. 
Bombesin/gastrin-related peptide 
Gastrin-related peptide (GRP) is the mammalian analogue 
of the amphibian peptide bombesin [102]. GRP stimulated 
the growth of cultured normal bronchial epithelial cells in 
a dose-dependent manner [111]. In vitro studies with cul- 
tured pulmonary NE cells demonstrated that reatment with 
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GRP increased the number of NE cells and stimulated their 
5-HT expression while treatment with 5-HT did not [99]. 
It has also been shown that GRP stimulated growth of small 
cell lung cancer cells [24]. This effect could be blocked in 
vivo by an antibody against GRP and in vitro by GRP an- 
alogues, which prevent binding of GRP to its receptor [24, 
64]. In vitro studies with the androgen-independent pros- 
tatic cancer cell line PC-3 similarly showed agrowth stim- 
ulatory action of GRP which could be blocked by an anti- 
GRP antibody [14], Saturable GRP-binding sites were 
demonstrated on PC-3 cells, but no immunoreactivity for
GRP was demonstrated in these cells, excluding an auto- 
crine action of GRP [14]. The GRP antagonist RC-3095 
was able to inhibit the growth of the androgen-dependent 
human xenograft PC-82, the Dunning R-3327H rat pros- 
tate tumor and the androgen-independent DU-145 and 
PC-3 prostatic in vitro cell lines [66, 80-82]. Saturable 
GRP-binding sites were demonstrated on cells of all these 
models. Altogether, evidence xists that GRP has a poten- 
tial role in the growth of (neoplastic) prostatic tissue. 
Calcitonin 
The human (hCT) and salmon (sCT) subtypes of CT can 
be demonstrated in a subset of normal and neoplastic pros- 
tatic cells [4, 8, 27, 29, 35, 40, 94, 96]. In conditioned me- 
dium of cultures of prostate cancer cells, immunoreactive 
CT was found in a concentration fourfold higher than in 
cultures of BPH cells [94]. In vivo administration f sCT 
to rats induced ornithine decarboxylase (a key enzyme as- 
sociated with cell cycle progression and growth) in a num- 
ber of organs [73]. It should be realized that CT also in- 
hibits the pituitary secretion of luteinizing hormone, which 
is an important hormone in the mediation of androgen se- 
cretion [62]. In addition, the secretion of prolactin, which 
influences the action of androgens on the prostate, was also 
found to be decreased by CT [12]. Therefore, apituitary- 
mediated growth-inhibiting effect of CT on prostatic an- 
cer growth is also expected. The direct growth-modulat- 
ing effects of CT have been studied in a few tumor systems. 
T-47D breast cancer cells contained high-affinity receptors 
for CT, and in vitro growth of these cells was dose depen- 
dently inhibited by CT [51, 75]. Comparable r sults were 
found in cells of the human gastric carcinoma cell line 
KATO III [72]. Following CT administration, i tracellular 
cAMP levels increased [51, 72, 75]. This increase was also 
found in four out of six renal adenocarcinoma cell lines 
and only these four cell lines were growth inhibited by CT 
administration [58]. In a panel of 13 small cell lung can- 
cer cell lines, 2 contained CT and only 1 was able to bind 
CT while no growth effect upon CT administration was 
found [11]. It has recently been shown that sCT dose de- 
pendently increased the cAMP concentration a d the DNA 
synthesis ncells of the in vitro human prostatic ancer cell 
line LNCaP [95]. The growth stimulatory effect of CT in 
LNCaP cells is at variance with the results from other non- 
prostatic tumor model systems [51, 58, 72, 75]. Therefore, 
the effects of CT have to be confirmed in additional stud- 
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ies using other prostatic tumor models including in vivo 
models because CT also has systemic effects which may 
influence prostatic tumor growth. 
Somatostatin 
Abrahamsson et al. [4] found somatostatin (SMS) immu- 
noreactivity in 12 out of 40 prostatic adenocarcinomas,  
result that has not been confirmed by Aprikian et al. [8]. 
SMS receptors were found neither in 17 prostatic arcino- 
mas nor in 2 BPH specimens [85]. On the other hand, bind- 
ing sites for several SMS analogs were demonstrated in 
normal and neoplastic prostatic tissues [100]. A number of 
experimental studies concerning the growth-modulating 
effects of SMS in prostate cancer have been published. Sev- 
eral SMS analogs (sandostatin, somatuline, RC-160, RC- 
121) decreased without exception the growth of prostatic 
tumor models in vivo (Dunning R-3327 and R-3327H, PC- 
82, DU-145, PC-3) and in vitro (LNCaP) [13, 19, 54, 66, 
69, 80, 82, 89, 97, 113]. In the Dunning R-3327H rat tu- 
mor the SMS effect potentiated the castration-induced 
growth inhibition even when the tumors became androgen 
independent [13]; however, this was not confirmed by oth- 
ers [97]. In experiments with heterotransplants of the an- 
drogen-independent PC-3 cell line, SMS was able to in- 
hibit growth only if the tumors were small (10 mm 3) [82]. 
Combination treatment of tumor models with an SMS an- 
alog and luteinizing hormone-releasing hormone (LH-RH) 
analog (D-TRP 6 LH-RH) resulted in a stronger growth in- 
hibition than treatment with only one of the components 
[54, 66, 89]. SMS-binding sites were demonstrated oncells 
of the PC-82 [66], Du-145 [80], PC-3 [82] and Dunning R- 
3327H [54] models. SMS and prolactin-binding sites were 
found to be downregulated in Dunning R-3327H tumors 
treated with analogs of SMS and LH-RH [54]. As noted 
above, prolactin may have a stimulating effect on prostate 
cancer, and the downregulation fthe prolactin receptor by 
SMS might partially explain the growth-inhibiting effects 
of SMS. All these results trongly suggest adirect growth- 
inhibiting effect of SMS (analogs) in prostate cancer. 
The effects of some of the neuropeptides on prostate 
cancer growth have been investigated quite extensively. 
The relationship with androgen levels and androgen recep- 
tor activity, the action of a combination of neuropeptides 
and the mechanisms of action are poorly understood atthe 
moment. Furthermore, it is not clear whether the amounts 
of neuropeptides secreted by the NE cells are sufficient for 
biological activity on neighboring cells. For some of the 
neuropeptides, the presence of the corresponding receptor 
is not clear. Possibly other, as yet unknown, factors pro- 
duced by prostatic NE cells may be even more important. 
Neuroendocrine differentiation in prostatic tumor models 
To enhance our knowledge of NE differentiation i pros- 
tate cancer, experimental models with NE cells are urgently 
needed. A heterotransplantable model of a small cell pros- 
tatic carcinoma has been established [52, 53, 108]. An 
SCPC is biologically different from an adenocarcinoma 
and, therefore, this model is probably not useful for the 
study of the paracrine role of NE cells in prostatic adeno- 
carcinoma. None of the available prostatic tumor models 
contains NE cells as defined by immunoreactivity forCgA, 
5-HT, CT, SMS, NSE and thyroid-stimulating hormone, al- 
though two heterotransplantable human tumor models 
which were recently established in this laboratory contain 
CgA-positive cells (unpublished observation). 
Possibly, NE differentiation can be induced in non-NE 
prostatic tumor models. Transfection of v-ras H into DMS- 
53 small cell lung cancer cell line cells resulted in a cell 
line with increased NE features [63]. Transfection of both 
c-raf-1 and c -myc  oncogenes into SV-40-immortalized 
bronchial epithelial cells resulted in the generation of het- 
erotransplantable large cell carcinoma cell lines with an 
NE phenotype [78, 79]. These studies indicate that NE dif- 
ferentiation can be induced and that it is associated with 
the expression of certain (proto-) oncogenes. Future ex- 
periments have to show if a similar approach can be ap- 
plied to prostate cancer. 
Conclusion 
Knowledge about the function of NE cells in the human 
prostate and prostate cancer is limited. Evidence is, how- 
ever, accumulating that NE cells and tumors with NE cells 
are related to the androgen-independent and poorly differ- 
entiated types of prostate cancer. However, at the moment 
it cannot be excluded that NE differentiation is only an epi- 
phenomenon associated with dedifferentiation f a tumor. 
There is evidence that the secretion products of prostatic 
NE cells affect prostate cancer growth and possibly also 
affect tumor differentiation. Research directed towards 
identifying the role of NE cells in prostate cancer is likely 
to contribute to the understanding of the transition of an- 
drogen-dependent to androgen-independent prostate can- 
cer. 
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